Diagnosis and Prognostic Significance of c-Met in Cervical Cancer: A Meta-Analysis

Table 2

Results of meta-analysis on c-Met expression in cervical cancer.

Outcome of interest	Number of studies	Number of tissue samples	RR/WMD	95% CI	Heterogeneity (%)
Carcinoma and neoplasia	5	E c-Met = 266, C c-Met = 108	2.13	1.02–4.44	,	0.044	2.01
Neoplasia and normal tissue	5	E c-Met = 108, C c-Met = 105	2.76	1.43–5.34	,	0.003	3.01
DFS	2	E c-Met = 77, C c-Met = 86	0.59	0.37–0.93	,	0.025	2.24
OS	2	E c-Met = 77, C c-Met = 86	0.59	0.35–1.00	,	0.052	1.94
Stage	3	E c-Met = 35, C c-Met = 263	1.33	0.97–1.82	,	0.073	1.79
Cancer cell types	5	E c-Met = 359, C c-Met = 103	1.05	0.81–1.37	,	0.697	0.39
Lymph node involvement	7	E c-Met = 173, C c-Met = 392	1.28	1.08–1.52	,	0.005	2.78
Deep stromal invasion	2	E c-Met = 57, C c-Met = 85	1.31	0.85–2.00	,	0.220	1.23
Differentiation grade	5	E c-Met = 129, C c-Met = 303	1.28	0.98–1.67	,	0.070	1.81
Age	2	E c-Met = 78, C c-Met = 64	0.71	0.50–1.01	,	0.058	1.9
Parametrial involvement	3	E c-Met = 45, C c-Met = 122	2.05	0.93–4.50	,	0.074	1.79
LVSI	3	E c-Met = 122, C c-Met = 204	1.16	1.01–1.34	,	0.038	2.07
Tumor size	2	E c-Met = 56, C c-Met = 86	1.06	0.74–1.51	,	0.758	0.31

C: control group; E: experiment group; RRs: risk ratios; WMD: weighted mean difference; CI: confidence interval; OS: overall survival; DFS: disease-free survival; : heterogeneity detection; LVSI: lymphovascular space invasion.